Literature DB >> 24242680

Morbidity associated with colostomy reversal after cytoreductive surgery and HIPEC.

Erienne M V de Cuba1, Victor J Verwaal, Ignace H J T de Hingh, Leonieke J J van Mens, Simon W Nienhuijs, Arend G J Aalbers, Hendrik J Bonjer, Elisabeth A te Velde.   

Abstract

BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has improved the survival in selected colorectal cancer patients with peritoneal metastases. In these patients, the risk of a low anastomosis is sometimes diminished through the creation of a colostomy. Currently, the morbidity and mortality associated with the reversal of the colostomy in this population is unknown.
METHODS: Our study involved two prospectively collected databases including all patients who underwent CRS-HIPEC. We identified all consecutive patients who had a colostomy and requested a reversal. The associations between four clinical and ten treatment-related factors with the outcome of the reversal procedure were determined by univariate analysis.
RESULTS: 21 of 336 patients (6.3 %) with a stoma with a mean age of 50.8 (standard deviation 10.2) years underwent a reversal procedure. One patient was classified as American Society of Anesthesiologists (ASA) grade III, 6 as ASA grade II, and the remaining as ASA grade I. Median time elapsed between HIPEC and reversal was 394 days (range 133-1194 days). No life-threatening complications or mortality were observed after reversal. The reversal-related morbidity was 67 %. Infectious complications were observed in 7 patients (33 %). Infectious complications after HIPEC were negatively correlated with the ultimate restoration of bowel continuity (P = 0.05). Bowel continuity was successfully restored in 71 % of the patients.
CONCLUSIONS: Although the restoration of bowel continuity after CRS-HIPEC was successful in most patients, a relatively high complication rate was observed. Patients with infectious complications after HIPEC have a diminished chance of successful restoration of bowel continuity.

Entities:  

Mesh:

Year:  2013        PMID: 24242680     DOI: 10.1245/s10434-013-3370-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

1.  The effects of platelet-rich-plasma gel application to the colonic anastomosis in hyperthermic intraperitoneal chemotherapy: An experimental rat model.

Authors:  Sonmez Ocak; Omer F Buk; Bugra Genc; Bahattin Avcı; Hatice O Uzuner; Salih B Gundogdu
Journal:  Int Wound J       Date:  2019-08-25       Impact factor: 3.315

2.  Implications of Stoma Formation as Part of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Authors:  H Jacoby; Y Berger; L Barda; N Sharif; Y Zager; A Lebedyev; M Gutman; A Hoffman
Journal:  World J Surg       Date:  2018-07       Impact factor: 3.352

Review 3.  The Role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendiceal Tumors and Colorectal Adenocarcinomas.

Authors:  Michael Kuncewitch; Edward A Levine; Perry Shen; Konstantinos I Votanopoulos
Journal:  Clin Colon Rectal Surg       Date:  2018-09-04

4.  Short-term outcome in patients treated with cytoreduction and HIPEC compared to conventional colon cancer surgery.

Authors:  Geert A Simkens; Vic J Verwaal; Valery E Lemmens; Harm J Rutten; Ignace H de Hingh
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

5.  Readmissions after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy-a national population-based study.

Authors:  Paul Dranichnikov; Wilhelm Graf; Peter H Cashin
Journal:  World J Surg Oncol       Date:  2020-04-06       Impact factor: 2.754

6.  Safety of coloanal/ileoanal anastomosis during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: results of 20 consecutive patients.

Authors:  Ozgul Duzgun; Murat Kalin
Journal:  J Int Med Res       Date:  2019-09-10       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.